Clinical case of benralizumab use in severe eosinophilic bronchial asthma in the Republic of Dagestan

Abstract

This article presents the results of the examination, observation, and treatment of a patient with severe persistent bronchial asthma with an eosinophilic phenotype who received benralizumab (Fazenra) in a complex treatment. Benralizumab is indicated for patients with severe bronchial asthma with an eosinophilic phenotype in adult patients as an additional maintenance therapy, in which the use of glucocorticosteroids does not achieve control over the symptoms of the disease. With complex therapy, the inclusion of benralizumab led to positive dynamics of both clinical symptoms and indicators of respiratory function, which allowed us to reduce the volume of therapy with corticosteroids and achieve disease control. The above case is of interest to both pulmonologists and therapists.

Keywords

clinical case / eosinophilic phenotype / atopic severe persistent bronchial asthma / treatment / monoclonal antibodies to the interleukin-5 receptor / benralizumab

References

[1] Asthma. Key facts [Internet] WHO. Available from: http://www.who.int/ru/news-room/fact-sheets/detail/asthma. Accessed 26.09.2021.

[2] Астма. Информационный бюллетень [Электронный ресурс] // ВОЗ. Режим доступа: http://www.who.int/ru/news-room/fact-sheets/detail/asthma. Дата обращения: 26.09.2021.

[3] Global Initiative for Asthma. GINA Report, Global Strategy for Asthma Management and Prevention (2022 updated) [Internet]. Available from: https://ginasthma.org. Accessed: 17.11.2023.

[4] Global Initiative for Asthma. GINA Report, Global Strategy for Asthma Management and Prevention (2022 updated) [Электронный ресурс]. Режим доступа: https://ginasthma.org. Дата обращения: 17.11.2023.

[5] Bystritskaya EV, Bilichenko TN. Review of the general incidence of bronchial asthma in the population of the Russian Federation. Pulmonologia. 2022;32(5):651–660. (In Russ.) DOI: 10.18093/0869-0189-2022-32-5-651-660

[6] Быстрицкая Е.В., Биличенко Т.Н. Обзор общей заболеваемости населения Российской Федерации бронхиальной астмой // Пульмонология. 2022. Т. 32, № 5. С. 651–660. DOI: 10.18093/0869-0189-2022-32-5-651-660

[7] Belevsky AS, Zaitsev AA. Pharmacoeconomical aspects of bronchial asthma therapy: real clinical practice. Medical Council. 2018;(15):60–68. (In Russ.) DOI: 10.21518/2079-701X-2018-15-60-68

[8] Белевский А.С., Зайцев А.А. Фармакоэкономические аспекты терапии бронхиальной астмы: реальная клиническая практика // Медицинский совет. 2018. № 15. С. 60–68. DOI: 10.21518/2079-701X-2018-15-60-68

[9] Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108:1723–1732. DOI: 10.1016/j.rmed.2014.10.007

[10] Schleich F., Brusselle G., Louis R. et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR) // Respir. Med. 2014. Vol. 108. P. 1723–1732. DOI: 10.1016/j.rmed.2014.10.007

[11] Sergeeva G, Emelyanov A, Leshenkova E, Znakhurenko A. Biomarkers of eosinophilic airways inflammation in patients with severe asthma: a reallife study. Allergy. 2019;74(S106):ТР0640. DOI: 10.1111/all.13961

[12] Sergeeva G., Emelyanov A., Leshenkova E., Znakhurenko A. Biomarkers of eosinophilic airways inflammation in patients with severe asthma: a reallife study // Allergy. 2019. Vol. 74, No. S106. P. ТР0640. DOI: 10.1111/all.13961

[13] Tran TN, Khatry DB, Ke X, et al. High blood eosinophil count is associated with more frequent asthma. Ann Allergy Asthma Immunol. 2014;113(1):19–24. DOI: 10.1016/j.anai.2014.04.011

[14] Tran T.N., Khatry D.B., Ke X. et al. High blood eosinophil count is associated with more frequent asthma // Ann. Allergy Asthma Immunol. 2014. Vol. 113, No. 1. P. 19–24. DOI: 10.1016/j.anai.2014.04.011

[15] Avdeev SN, Nenasheva NM, Zhudenkov KV, et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in the Russian Federation. Pulmonology. 2018;28(3):341–358. (In Russ.) DOI: 10.18093/0869-0189-2018-28-3-341-358

[16] Авдеев С.Н., Ненашева Н.М., Жуденков К.В. и др. Распространенность, заболеваемость, фенотипы и другие характеристики тяжелой бронхиальной астмы в Российской Федерации // Пульмонология. 2018. Т. 28, № 3. С. 341–358. DOI: 10.18093/0869-0189-2018-28-3-341-358

[17] Federal’nye klinicheskie rekomendatsii: Bronkhial’naya astma. 2021. [Internet] 16.06.2023. Available from: https://cr.minzdrav.gov.ru/recomend/359_2. Accessed: 17.11.2023. (In Russ.)

[18] Федеральные клинические рекомендации: Бронхиальная астма. 2021 [Электронный ресурс]. Режим доступа: https://cr.minzdrav.gov.ru/recomend/359_2. Дата обращения: 16.06.2023.

[19] Global Initiative for Asthma. Difficult-to-treat severe asthma in adolescent and adult patients. Diagnosis and Management. 2022 [Internet]. Available from: https://ginasthma.org. Accessed: 17.11.2023.

[20] Global Initiative for Asthma. Difficult-to-treat severe asthma in adolescent and adult patients. Diagnosis and Management. 2022. [Электронный ресурс]. Режим доступа: https://ginasthma.org. Дата обращения: 17.11.2023.

[21] Arkhipov VV, Grigorieva EV, Gavrishina EV. Control of bronchial asthma in Russia: results of a multicenter observational study of NIKA. Pulmonology. 2011;(6):87–93. (In Russ.) DOI: 10.18093/0869-0189-2011-0-6-87-93

[22] Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА // Пульмонология. 2011. № 6. С. 87–93. DOI: 10.18093/0869-0189-2011-0-6-87-93

[23] Bourdin A, Husereau D, Molinari N, et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors: systematic review. Eur Respir J. 2018;52(5):1801–1393. DOI: 10.1183/13993003.01393-2018

[24] Bourdin A., Husereau D., Molinari N. et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors: systematic review // Eur. Respir. J. 2018. Vol. 52, No. 5. P. 1801–1393. DOI: 10.1183/13993003.01393-2018

[25] Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10(1):47–58. DOI: 10.1016/S2213-2600(21)00352-0

[26] Menzies-Gow A., Gurnell M., Heaney L.G. et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study // Lancet Respir. Med. 2022. Vol. 10, No. 1. P. 47–58. DOI: 10.1016/S2213-2600(21)00352-0

[27] FitzGerald JM, Bleecker ER, Nair P et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141. DOI: 10.1016/S0140-6736(16)31322-8

[28] FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial // Lancet. 2016. Vol. 388. P. 2128–2141. DOI: 10.1016/S0140-6736(16)31322-8

[29] Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127. DOI: 10.1016/S0140-6736(16)31324-1

[30] Bleecker E.R., FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial // Lancet. 2016. Vol. 388. P. 2115–2127. DOI: 10.1016/S0140-6736(16)31324-1

[31] Bao-ping T, Gen-sheng Z, Jian L, et al. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials. Journal of Asthma. 2017. DOI: 10.1080/02770903.2017.1379534

[32] Bao-ping T., Gen-sheng Z., Jian L. et al. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials // Journal of Asthma. 2017. DOI: 10.1080/02770903.2017.1379534

[33] Korn S, Bourdin A, Chupp G, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021;9(12):4381–4392.e4. DOI: 10.1016/j.jaip.2021.07.058

[34] Korn S., Bourdin A., Chupp G. et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years // J. Allergy Clin. Immunol. Pract. 2021. Vol. 9, No. 12. P. 4381–4392.e4. DOI: 10.1016/j.jaip.2021.07.058

RIGHTS & PERMISSIONS

Eco-Vector